The evidence base for many aspects of the management of foot ulcers in people with diabetes is weak, and goodquality research, especially relating to studies of direct relevance to routine clinical care, is needed. In this paper, we summarise the core details required in the planning and reporting of intervention studies in the prevention and management of diabetic foot ulcers, including studies that focus on off -loading, stimulation of wound healing, peripheral artery disease, and infection. We highlight aspects of trial design, conduct, and reporting that should be taken into account to minimise bias and improve quality. We also provide a 21-point checklist for researchers and for readers who assess the quality of published work.
Introduction
Foot ulcers pose an enormous problem for people with diabetes, 1 and their prevention and management are undermined by the scarcity of evidence on which to base treatment choices. Many systematic reviews [2] [3] [4] [5] [6] [7] have repeatedly drawn attention to the urgent need for higherquality studies in both prevention and management. Despite this call for action and the escalating size of the clinical problem, the number of reports of high-quality research into interventions for diabetic foot ulcers has remained low. [2] [3] [4] [5] [6] There is no shortage of guidance available on the general principles of trial design, conduct, and reporting, and researchers are already encouraged to use one of several checklists when planning and conducting their research. These include the CONSORT statement for randomised trials, 8 STROBE for epidemiological studies, 9 and PRISMA for systematic reviews and metaanalyses. 10 Systems for scoring studies of diff erent design 11 and guidance on the assessment of published evidence-notably, the GRADE system 12 -also exist. These principles have been incorporated into two guidance documents for studies of chronic wounds published by the European Wound Management Association (EWMA), 13, 14 but no guidelines have so far been produced that are specifi c for studies in the complex clinical area of foot ulcers in diabetes. Part of the reason for this lies in the large number of overlapping processes involved in the development and presentation of foot ulcers and in their protracted healing, and their eff ects on all aspects of trial design. Therefore, in this paper, we outline standards for the design and reporting of studies of foot ulcers in diabetes, although this paper is intended to be read in conjunction with the less specifi c reports published by the EWMA. 13, 14 These standards are directed at those who design and undertake the research, and those who read and assess the reports. We hope that by defi ning the criteria that need to be specifi ed in research articles, this paper will lead to an improvement in the quality of the research conducted and submitted for publication. Finally, through doing repeated systematic reviews, we found that existing tools for assessing the literature do not fully meet the needs of research in this complex clinical area; therefore, we also include a checklist as both a guide to authors and a tool for readers to assess the quality of reported work.
This defi nition of standards for the design and reporting of research into disease of the foot in diabetes is limited to interventions designed to improve either the prevention or the management of foot ulcers, and excludes other forms of diabetic foot disease. Although consideration is given to studies targeting diff erent pathogenic factors (eg, neuropathy, deformity, peripheral artery disease, and infection), we primarily focus on research that is of direct clinical relevance. These guidelines do not include work on specifi c underlying biological mechanisms or processes, observational (noninterventional) research, or work in animal models. The paper is also limited to studies of effi cacy and eff ectiveness, and does not consider health-economic aspects.
Core details for reports of intervention studies
Many details should be documented in intervention studies, but they vary depending on the specifi c area of research. They also vary between studies of ulcer prevention and management (table 1) , and between studies concerning off -loading, associated peripheral artery disease, and infection (table 2). The details of studies can be divided into those relating to the population (whether of the person, the limb, or the ulcer), interventions, and outcomes, and they will vary according to the primary objective or area of interest of the study. The items listed in tables 1-2 should be considered as essential for inclusion in reports, even though the detail for each report will vary with the study type. Failure to include some or many of these details is the reason that so few high-quality papers have been identifi ed in systematic reviews. [2] [3] [4] [5] [6] [7] 
Personal View
The protocol and report should include defi nitions of key terms appropriate to the study, such as "ulcer", "healing", "deformity", "peripheral artery disease", "neuropathy", and "infection". When relevant, the defi nition should be accompanied by the criteria or the tests used to make the diagnosis. To facilitate uniform reporting that renders comparison of studies possible, researchers are advised to use the set of core defi nitions on patient characteristics, treatment, and outcome provided by the International Working Group on the Diabetic Foot (IWGDF). 15 Personal View Table 1 summarises the core data to be considered in the design and reporting of prevention studies. The population details can be divided into those relating to the person, the limb, and the ulcer. The minimum requirements for the person details are age, sex, and ethnicity, because all three are relevant to the onset of new ulcers, which are more common in men, in older people, and in white individuals. 16 The presence of relevant comorbidities-eg, established renal failure, heart failure, immobility, impaired vision, or a combination of these-should also be reported. Participants should be classifi ed as being at low, medium, or high risk of new ulceration using a scheme such as that adopted by the IWGDF, 17 in which the classifi cation of risk is based on the presence of neuropathy, peripheral artery disease or foot deformity, previous history of foot ulceration, or amputation. Because a very large sample size might be required to study prevention in low-risk populations, the usual practice is to base research on populations at high risk. The group with the highest risk includes those who have had an ulcer previously; the incidence of ulcer recurrence is roughly 30-40% in the fi rst 12 months after healing. 18, 19 Other details will depend on the focus of the study (eg, whether it is concerned with education, footwear, or the correction of risk factors such as deformity, use of footwear, or peripheral artery disease). Educational studies require documentation of educational status; in studies of self-care behaviour, the capacity for self-care should be described. Documentation of socioeconomic status might also be relevant if it is feasible.
Prevention of foot ulcers in diabetes

Studies of foot ulcer prevention Population
The volume and precision of data collection is aff ected by the size of the study population. The incidence of new ulceration in an unselected population with diabetes is low (eg, roughly 2% per year in a low-risk population in the UK); thus, a large sample size is required for studies examining the eff ect of an intervention on ulcer incidence in such a population-approximately 10 000 individuals are needed to show a reduction in ulcer incidence to 1·5%, depending on study duration, anticipated withdrawals, and power. The amount of baseline data that can be reliably obtained from such a large study population is necessarily limited, by contrast with smaller studies in which more detailed data can be recorded.
Interventions
Various interventions can be explored with respect to prevention (table 1) , and their description should be Table 2 : Additional core details for the reporting of intervention studies in the management of existing diabetic foot ulcers Personal View detailed enough to enable another researcher to replicate the study. In studies of footwear, for example, it is not suffi cient to simply state that the intervention was custom made; details of the customisation must be provided.
As in studies of ulcer management (discussed below), studies of ulcer prevention should specify the approach for usual foot care in diabetes in the comparator group, including the frequency of routine surveillance to document the degree of ulcer risk, the approach to mitigate risk factors (eg, deformity, abnormal pressure loading, and peripheral artery disease), the provision of foot-care education, the frequency of surveillance for those at moderately increased risk, and the frequency of surveillance for those at greatly increased risk.
Outcomes
The outcomes for the foot or limb or for the person can be direct or surrogate (table 1) . In prevention studies, the primary outcome measure is preferably the incidence of new ulceration, expressed as the proportion of the population (in both absolute numbers and percentages) who have a new ulcer by a fi xed time, or as the time to new ulceration, or both. Ulcer defi nition is a minimal requirement. If more than one ulcer risk group is included, outcomes should be reported for each group separately. In some instances, it will also be important to record the ulcer type and site, and whether the ulcer occurs at the same site as the previous ulcer (ie, a recurrence) or at a new site.
Other prevention studies use surrogate outcome measures-eg, change in foot self-care (for educational, behavioural, or other psychological intervention studies directed at patients), change in foot examination skill or frequency (for patients or health-care professionals), and change in foot pressure (for footwear studies). Studies of the eff ect of footwear or surgery on plantar foot ulcer incidence should provide evidence of the effi cacy of these interventions to reduce pressure underneath the foot, based on barefoot or in-shoe measures made with a validated plantar pressure measurement system. Additionally, footwear studies should provide data for adherence to wearing the prescribed shoe using diaries or, preferably, wearable technology such as activity and footwear use monitors. For self-care management, data for adherence and false-positive and false-negative outcomes in seeking professional help are important, because they can contribute to the cost-eff ectiveness and acceptance of the intervention in clinical practice.
Studies of the management of existing diabetic foot ulcers Population
When the population studied is a mixed one (eg, studies including both venous ulcers of the lower leg and diabetic foot ulcer, or studies including people with and without diabetes), the subpopulation of interest-ie, those with diabetic foot ulcers-needs to be separately described and analysed, with specifi c reference to sample size, baseline characteristics, withdrawals, and outcome. History of previous ulceration or amputation might also be important and should be specifi ed in studies that include recurrence or new ulceration as an endpoint. The setting of the study (eg, primary, secondary, or tertiary care; one or multiple centres) should be described to indicate the generalisability.
In addition to core population details-including age, sex, ethnicity, and the type and duration of diabetes and comorbidities-the extent of coexisting neuropathy (ie, reduced sensation), peripheral artery disease, and foot deformity should be documented because they can all contribute to ulcer onset. Although several diff erent tests are used in clinical practice to defi ne neuropathy (eg, tests of 10 g monofi lament, light touch, pain, and vibration), there is no standard criterion for every circumstance. The minimum requirement is usually accepted as foot sensation documented with a 10 g monofi lament, although some researchers might use a diff erent stimulus (eg, vibration perception). At present, the minimum details accepted for defi ning the presence of peripheral artery disease in an ulcer study are pulse palpability and the ankle-brachial pressure index. However, neither of these measures is without fl aws, and further tests might be necessary, depending on the nature of the study (table 2) . In studies in which the primary focus is interventions for peripheral artery disease, the population needs to be defi ned with more precise anatomical and functional markers (table 2). In studies involving vascular interventions on both legs, one limb should be chosen as index leg and only the fi ndings of this leg should be reported. There is no accepted way of documenting the degree of foot deformity in clinical practice; therefore, the inclusion of foot deformity is inevitably subjective. However, if foot deformity is relevant, then its nature and severity should be described.
The ulcer needs to be described, and several classifi cation schemes are available for the documentation of ulcer characteristics. 20 Not all of these schemes include all the details required for all studies. Reports should, however, specify the number of active ulcers; the site, duration, type, area, and depth of the index ulcer; and the presence or absence of infection (table 1). People often have more than one ulcer, and those who do have a worse overall prognosis than do those who have only one ulcer. In individuals with multiple ulcers, one ulcer should usually be selected for the study (ie, the index ulcer). The index ulcer is usually the largest or the one judged the most clinically important, even though this defi nition depends on the chosen study criteria. In studies in which the endpoint is healing of all ulcers (and the foot being ulcer free), then all ulcers are considered together as a group.
Increased area and depth of the ulcer are associated with healing delay, and both need to be documented, as do the methods used to determine them. Area is usually documented after debridement but this needs to be Personal View stated. Ulcer depth is best classifi ed by anatomical depth (as in the University of Texas, IWGDF, and SINBAD [site, ischaemia, neuropathy, bacterial infection, area, and depth] classifi cation systems 20 ) rather than in millimetres. The anatomical site should be specifi ed because this aff ects the choice of intervention and the rate of healing.
For studies in which infection is the primary interest, the population needs to be carefully defi ned (table 2). The diagnosis of infection is primarily clinical and is based on the criteria of the Infectious Diseases Society of America 21 and the IWGDF. 22 In most cases, studies will be concerned with the treatment of clinically overt foot infection. Such studies can select those with either soft tissue infection alone or soft tissue infection combined with osteomyelitis; the criteria used to defi ne or exclude any osteomyelitis must be stated. Studies may or may not include ulcers that are infected at recruitment, but if they do, the defi nition and severity of infection need to be described.
When assessing the eff ectiveness of new treatments for wound care and off -loading in cases of so-called hardto-heal ulcers, it is becoming more common to specify that a study ulcer has failed to heal despite management in a specialist centre according to accepted principles of good standard care (see below). As such, the duration of the ulcer needs to be defi ned, and the ulcer needs to have persisted without decreasing by more than a stated percentage in cross-sectional area (40% or 50%) or other aspect of size (eg, diameter, depth, or volume). The logic for this requirement is that, in most cases, new (and often expensive) treatments should not be used for ulcers that are likely to heal with good standard care. The adopted principles of good standard care should be described (see below).
Nevertheless, so-called hard-to-heal ulcers might include ulcers that have sometimes been present for very long periods, and their failure to heal might derive from a complex interaction between biological, social, and personal factors. In such cases, the chances of one treatment being shown to be eff ective might be reduced, and this issue can be circumvented by including an upper limit for ulcer duration (such as 12 or 24 months).
Interventions
The management of diabetic foot ulcers is multifaceted, and the intervention to be tested should usually be provided in addition to general good standard care. The design of many studies will involve the comparison of outcome in those receiving the intervention plus good standard care with the outcome in a similar group receiving a diff erent intervention plus good standard care or a group receiving good standard care alone. Occasionally, the comparator group might be managed with so-called usual care, implying that no eff ort has been made to ensure that such care fulfi ls all the criteria of good standard care. Although this is not ideal, it might be a pragmatic solution, particularly in a study designed to document eff ectiveness in a large population as opposed to effi cacy in a smaller, more tightly defi ned, one.
The principles of good standard care include a formal assessment of the ulcer and surrounding skin at each clinic review; provision of any necessary off -loading, with detailed description of the type and assessment of its eff ectiveness; debridement of the wound surface, which can be surgical (either in the clinic or in an operating room) or non-surgical; selection of appropriate dressing products; appropriate antimicrobial therapy (for clinically infected wounds only); attention to nutrition and self-care; attempt to achieve optimal glycaemic control; assessment for peripheral artery disease, with consideration of revascularisation where appropriate; and continued close observation with appropriate adjustment of management.
Outcomes
The outcome that most people want is to survive, have improved quality of life, optimal mobility, and be ulcer free as soon as possible-without the need for surgery or hospital admission-and without recurrence (table 1) . Therefore, overall long-term outcome of the intervention might be survival (at a fi xed time) without continuing ulceration and with unaided mobility intact. The use of quality-of-life measures should also be considered.
If a person undergoes surgery, its nature needs to be defi ned: surgical debridement with or without local intervention such as grafting, minor amputation (defi ned as transverse removal of part of the lower limb below the ankle joint), 15 and major amputation (transtibial, through knee, or transfemoral). 15 The extent of any postoperative morbidity (eg, wound infection or transfer ulceration) should be documented. When surgical or endovascular procedures are assessed, 30 day mortality and preferably also long-term mortality should be reported. The incidence of major amputation should never be considered in isolation from death, because there are many people who die during follow-up and who would have had a major amputation if their overall prognosis was not so poor. Early major amputation is recognised to be the best treatment for some individuals, and while the incidence of limb loss through amputation should be recorded, death during the study, both with and without preceding major amputation, also needs to be documented. The term limb salvage (which means survival without major amputation) has become popular in some specialty areas, but it is poorly defi ned and is therefore not recommended. The preferred term is amputation-free survival.
Ulcer healing is usually defi ned as complete epithelialisation after removal of callus without discharge, which is maintained for a minimum of 2 weeks (as required by the US Food and Drug Administration). Any ulcer that occurs after the time specifi ed is regarded as a recurrence. It is important to also specify whether healing follows a surgical procedure (such as fl ap or grafting) or whether it is by secondary intention. Healing can be recorded as the number (or percentage) of index ulcers Personal View healed by a fi xed time from randomisation (or the start of the observation period in non-randomised studies), or as the time to healing. The term "rate of healing" is ambiguous because it can refer to the incidence of healing, the time to healing, or the percentage reduction in cross-sectional area and should therefore be avoided. A further problem inherent in the use of either the number (or percentage) of ulcers healed by a fi xed time or the time to healing is that these metrics are directly related to baseline ulcer area, because larger ulcers take longer to heal. It is therefore important to ensure that intervention and control groups include near-equal numbers of ulcers of diff erent sizes.
Change in ulcer area can be used as a surrogate endpoint, but measurement of ulcer area presents its own problems. The contour of the foot underlying an ulcer is nearly always curved, meaning that measurements taken from digital images are not precise. Therefore, the methods used to measure cross-sectional area need to be documented. Newer commercial imaging systems are increasingly used, and some might allow the assessment of changes in ulcer volume; however, they tend to be expensive. Several other ulcer-related outcomes can be used as surrogate endpoints, including measures of clinical wound appearance and status, especially in shorter-term studies.
For studies focused on infection, the choice of outcome will be determined by the study design and, in particular, whether the aim is to assess the use of a non-surgical antimicrobial treatment without surgery or an intervention that combines the two. The aim of most such studies will be the resolution of infection, defi ned as the disappearance of, or suffi cient improvement in, signs and symptoms related to the infection such that no further treatment is required. Ulcer healing is not a specifi c measure of the resolution of infection. Resolution of infection can be achieved either by the use of non-surgical antimicrobial treatment (including antibiotics via topical, local, or systemic routes) or by antimicrobial therapy in combination with surgery. If the study aims to assess an antimicrobial regimen, then the use of surgery might be considered as an outcome (indicating incomplete eff ect), whereas in studies of a combined approach, the use of surgery might simply be a detail of the intervention. When assessing non-surgical interventions (eg, an antibiotic regimen), the resolution of infection can be determined at diff erent stages-at specifi ed points during treatment, at the end of treatment, or at a specifi ed time after the end of treatment (usually called test of cure). Such studies often also include microbiological outcomes, but consideration of these is beyond the scope of this paper. Moreover, the eradication of clinical infection cannot be defi ned by the results of microbiological testing.
In studies of peripheral artery disease, the outcomes will be specifi c to revascularisation (eg, outfl ow in the foot), even though ulcer healing might be used as a secondary outcome measure (table 2) . Of note, none of the existing classifi cations for the eff ects of peripheral artery disease is entirely appropriate for people with diabetic foot ulcers.
All intervention studies should include a formal documentation of adverse events and adverse device eff ects, regardless of whether they are serious. Adverse events might include, but are not restricted to, hospital admissions, infection, onset of an acute Charcot foot, new ulcer formation, amputation, death, and-especially in the case of off -loading interventions-falls, abrasions, hyperkeratosis, and blisters.
The effi cacy or eff ectiveness of an intervention cannot be assessed unless the completeness of intervention delivery is documented. One example relates to the use of off -loading, in which it can be important to show not only that off -loading has been prescribed, but also that it is eff ective in terms of reducing the forces applied to the foot or to the healing wound and that the device is worn as prescribed (ie, compliance, adherence, or concordance).
Markers of good quality
Some of the details in the above sections should be used to defi ne the quality of the resulting publication. Quality largely refers to the extent to which a study and its report are free from bias-ie, the reported observations and conclusions are most probably the result of the intervention and unlikely to have been aff ected by other factors. To help with the assessment of quality, we provide a checklist for intervention studies of diabetic foot ulcers (panel). Many criteria listed are relevant to the management of chronic wounds, as detailed in the two publications by the EWMA. 13, 14 Many criteria in this checklist also overlap with those in the CONSORT guidelines, 8 which are widely applied by journal editors when considering papers for publication.
In addition to providing guidance to investigators on the design and reporting of research in this area, the aim of this checklist is to include criteria that can be used to grade the quality of the report and thereby give an indication of its potential relevance to routine clinical practice. The ability to grade publications in this way is of great importance in the assessment of individual publications and also for the conduct of systematic reviews. Several generic scoring schemes already exist but, in our own experience, these schemes do not apply well to studies of diabetic foot ulcers.
The criteria are divided into four main groups: study design, study conduct, outcomes, and study reporting. The intention is that the desired answer for each item is "yes", and that each scores one point. Criteria have yet to be established to determine how the resultant scores (maximum 21) can be stratifi ed into appropriate levels of quality. The complete checklist is shown in the panel, although some notes regarding the interpretation and use of several criteria are provided below.
Personal View Study design: choice of study population (item 2)
If the study is being assessed from the point of view of clinical care, the following principles apply, even though some exceptions exist. First, the participants should be patients with diabetes who are at risk of developing a diabetic foot ulcer (for prevention studies) or whose disease is complicated by a diabetic foot ulcer (for intervention studies). Second, if more than one foot ulcer is present, only one (a specifi ed index ulcer) should be included per participant. Third, the type of ulcer chosen for a study of treatment should be appropriate for the type of intervention. This is relevant because many trials of new interventions were done in people with uncomplicated neuropathic ulcers, for which a cheap and eff ective treatment already existed (ie, off -loading). In practice, a new (and usually expensive) treatment will be reserved for ulcers that have failed to heal despite administration of good standard care in expert centres. Therefore, the eff ectiveness of new treatments should, in most cases, be assessed in participants with so-called hard-to-heal ulcers. To that end, the term "hard-to-heal" requires a defi nition.
Study design: defi nition of other aspects of care (item 5)
When an intervention is administered for the prevention or treatment of diabetic foot ulcers, it will inevitably be given in conjunction with other aspects of care (usual care or optimised, good standard care; see above). The components of other aspects of care must be described.
Study conduct: retention and attrition (item 13)
Many participants are lost to follow-up from studies of diabetic foot ulcers, not least because the population susceptible to foot disease is also prone to other complications of diabetes and comorbidities, and intercurrent illness is not uncommon. The longer the study duration, the higher the likelihood of intercurrent illness and thus loss to follow-up. If the primary outcome is based on ulcer healing, then the duration of the intervention is likely to last for 16, 20, or 24 weeks. If the primary endpoint is ulcer development in a prevention study, follow-up might be much longer. The lower the rate of retention (ie, the higher the rate of attrition or loss to follow-up), the greater the likelihood of bias in any observations made. There is no consensus on the rate of retention or attrition that is acceptable in this population in studies of diff erent duration but, in our opinion, the rate of attrition should be no greater than 25% in studies of ulcer management with an intervention phase of 20 weeks or more.
Outcomes: performance in the control group (item 16)
Some expensive new interventions have acquired widespread adoption as a result of studies that would now be regarded as fl awed. In some cases, the apparent benefi t of the new intervention was based on a signifi cant diff erence from the comparator group, when the diff erence could be accounted for by poor performance in the comparator group receiving usual care. It is therefore essential to scrutinise outcome in the comparator group and to check that performance is similar to that used as the basis for sample size calculation.
Conclusions
The paper is based on expert opinion and summarises the points that should be included in the design and reporting of clinical studies of the complex processes involved in the prevention and management of foot ulcers in diabetes. It The desired answer for each question is intended to be "yes", and each scores one point.
Study design
1 Are appropriate defi nitions included for the terms "ulcer", "healing", and all other required aspects of the population and the outcomes? 2 Was the choice of study population appropriate for the chosen intervention and the stated conclusions? 3 Was there a control population that was managed at the same time as those in the intervention group or groups? 4 Is the intervention suffi ciently well described to enable another researcher to replicate the study? 5 Are the components of other aspects of care described for the intervention and comparator groups? 6 Were the participants randomised into intervention and comparator groups? 7 Were the participants randomised by an independent person or agency? 8 Was the number of participants studied in the trial based on an appropriate sample size calculation? 9 Was the chosen primary outcome of direct clinical relevance? 10 Was the person who assessed the primary outcome or outcomes blinded to group allocation? 11 Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?
Study conduct
12 Did the study complete recruitment? 13 Was it possible to document the primary outcome in 75% or more of those recruited? 14 Were the results analysed primarily by intention-to-treat analysis? 15 Were appropriate statistical methods used throughout?
Outcomes 16 Was the performance in the control group of the order that would be expected in routine clinical practice? 17 Are the results from all participating centres comparable? Answer "yes" if the study was done in only one centre.
Study reporting
18 Is the report free from errors of reporting-eg, discrepancies between data reported in diff erent parts of the report? 19 Are the important strengths and weaknesses of the study discussed in a balanced way? 20 Are the conclusions supported by the fi ndings? 21 Is the report free from any suggestion that the analysis or the conclusions could have been substantially infl uenced by people with commercial or other personal interests in the fi ndings?
Personal View
is directed both at researchers planning clinical research in this area and at those who read and assess the reports of such work. It does not include detail on some fundamental aspects of trial design, which are covered in previous publications by the EWMA. 13, 14 Finally, it is also intended to be used as a template, which will need further details for studies in some subspecialty areas.
The production of lists of required data is fraught with diffi culty, not least because the details required for one type of study might sometimes be diff erent from those required in another type, even in the same specialty. It is this diffi culty that results in tables 1-2 being entitled "core details" because it is not possible to be more dogmatic. This is most true in the subspecialty areas of off -loading, peripheral artery disease, and infection. For each of these, as well as for research relating to specifi c interventions in wound healing, the lists provided will ultimately serve as a spine that can be used for the more detailed guidance required by those working in the area.
In addition to highlighting the core details for points to be considered in trial design and reporting, we have included a checklist of 21 items that can be used to assess the quality of work in the specialty of diabetic foot ulcers (panel). The higher the score achieved, the greater the chance that the reported study is free from bias and is relevant to clinical practice. This checklist aims to provide equal weight to aspects of study design, conduct, and reporting, and should also be considered as a tool for the conduct of systematic reviews in this complex clinical area. If these criteria are adopted in future reports, it is hoped that there will be overall improvement in the quality of published work in a clinical fi eld for which the evidence base is weak at present.
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